Peptide-major histocompatibility complex class II (pMHCII)-based nanomedicines displaying
tissue-specific autoantigenic epitopes can blunt specific autoimmune conditions by re …

Peptide MHC class II–based (pMHCII-based) nanomedicines trigger the formation of
multicellular regulatory networks by reprogramming autoantigen-experienced CD4+ T cells …

The development of autoimmunity results from a breakdown of immunoregulation and
involves cellularly complex immune responses against broad repertoires of epitope …

Regulatory T cells hold promise as targets for therapeutic intervention in autoimmunity, but
approaches capable of expanding antigen-specific regulatory T cells in vivo are currently not …

Nanotechnology offers enormous potential in drug delivery and in vivo imaging.
Nanoparticles (NPs), for example, are being extensively tested as scaffolds to deliver anti …

We have shown that nanoparticles (NPs) can be used as ligand-multimerization platforms to
activate specific cellular receptors in vivo. Nanoparticles coated with autoimmune disease …

The liver is an important immunological organ that controls systemic tolerance. The liver
harbors professional and unconventional antigen-presenting cells that are crucial for …

The association of autoimmune diseases with particular allellic products of the class-II major
histocompatibility complex (MHCII) region implicates the presentation of the offending self …

Liver malignancies are among the tumor types that are resistant to immune checkpoint
inhibition therapy. Tumor‐associated macrophages (TAMs) are highly enriched and play a …

Background & Aims It is well-known that the liver can induce immune tolerance, yet this
knowledge could, thus far, not be translated into effective treatments for autoimmune …